Alcon first in Asia

Article

Alcon's first 330,000 sq. ft. ophthalmic pharmaceutical manufacturing plant in Singapore is now under construction and is targeted for completion in 2012.

Alcon's first 330,000 sq. ft. ophthalmic pharmaceutical manufacturing plant in Singapore is now under construction and is targeted for completion in 2012.

It will serve the Asian markets and according to Alcon's senior vice president for global manufacturing and technological operations, Ed McGough: "With the rapid growth we are experiencing in Asia, this new Singapore plant is integral to our ability to meet the increasing demand for our products in the region. The strategically positioned Singapore location, coupled with the increased capacity of this plant, will help us supply Asia with essential eye care pharmaceuticals more efficiently, and maintain the high-quality service our customers have come to expect from Alcon."

Alcon Singapore operations were established in 1992. Currently the company employs 40 staff and it's anticipated that the new plant will create 150 new jobs.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.